Cholera and Pancreatic Cholera: Is VIP the Common Pathophysiologic Factor?
VIP
cholera patients
Journal
Tropical medicine and infectious disease
ISSN: 2414-6366
Titre abrégé: Trop Med Infect Dis
Pays: Switzerland
ID NLM: 101709042
Informations de publication
Date de publication:
02 Jul 2020
02 Jul 2020
Historique:
received:
31
05
2020
revised:
20
06
2020
accepted:
30
06
2020
entrez:
8
7
2020
pubmed:
8
7
2020
medline:
8
7
2020
Statut:
epublish
Résumé
Cholera remains a major global health problem, causing high output diarrhea leading to severe dehydration and shock in developing countries. We aimed to determine whether vasoactive intestinal polypeptide (VIP), the mediator of pancreatic cholera syndrome, has a role in the pathophysiology of human cholera. We conducted a prospective observational study of cholera cases hospitalized with severe dehydration. Plasma and stool water levels of VIP were measured just after admission, after complete rehydration (3-4 h), at 24 h post-rehydration and at discharge after diarrhea ceased. In total, 23 cholera patients were examined between January and August 2018. The geometric mean of stool VIP (sVIP) and plasma VIP (pVIP) on admission were 207.67 and 8.34 pmol/L, respectively. pVIP values were all within the normal range (</= 30 pcmol/L); however, sVIP levels were very high at all timepoints, though less so just after rehydration. In multivariable GEE models, after adjustment for covariates, sVIP levels were significantly associated with duration of hospitalization ( The data suggest that VIP, which is released by intestinal nerves, may play an important role in human choleragenesis, and inhibitors of intestinal VIP merit testing for potential therapeutic benefits.
Sections du résumé
BACKGROUND
BACKGROUND
Cholera remains a major global health problem, causing high output diarrhea leading to severe dehydration and shock in developing countries. We aimed to determine whether vasoactive intestinal polypeptide (VIP), the mediator of pancreatic cholera syndrome, has a role in the pathophysiology of human cholera.
METHODS
METHODS
We conducted a prospective observational study of cholera cases hospitalized with severe dehydration. Plasma and stool water levels of VIP were measured just after admission, after complete rehydration (3-4 h), at 24 h post-rehydration and at discharge after diarrhea ceased.
RESULTS
RESULTS
In total, 23 cholera patients were examined between January and August 2018. The geometric mean of stool VIP (sVIP) and plasma VIP (pVIP) on admission were 207.67 and 8.34 pmol/L, respectively. pVIP values were all within the normal range (</= 30 pcmol/L); however, sVIP levels were very high at all timepoints, though less so just after rehydration. In multivariable GEE models, after adjustment for covariates, sVIP levels were significantly associated with duration of hospitalization (
CONCLUSIONS
CONCLUSIONS
The data suggest that VIP, which is released by intestinal nerves, may play an important role in human choleragenesis, and inhibitors of intestinal VIP merit testing for potential therapeutic benefits.
Identifiants
pubmed: 32630790
pii: tropicalmed5030111
doi: 10.3390/tropicalmed5030111
pmc: PMC7559706
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Exp Biol. 1997 Jan;200(Pt 2):287-93
pubmed: 9050236
Gut. 1983 Jun;24(6):542-8
pubmed: 6852634
Biometrics. 1988 Dec;44(4):1049-60
pubmed: 3233245
Acta Physiol Scand. 1988 Aug;133(4):551-7
pubmed: 2906512
World J Surg. 1979 Sep 20;3(5):559-63
pubmed: 229653
J Gastroenterol Hepatol. 2003 Feb;18(2):203-10
pubmed: 12542607
Gastroenterology. 1984 Oct;87(4):845-7
pubmed: 6147293
Gut. 1995 Sep;37(3):340-5
pubmed: 7590428
Dig Dis Sci. 2012 Jan;57(1):19-27
pubmed: 22001941
Gut. 2000 Sep;47(3):382-6
pubmed: 10940276
Br J Pharmacol. 2002 Mar;135(6):1443-8
pubmed: 11906957
N Engl J Med. 1968 Jul 25;279(4):176-81
pubmed: 4968807
AIDS. 1993 Feb;7(2):223-6
pubmed: 8466684
Arch Dis Child. 1986 Apr;61(4):372-6
pubmed: 3518641
Gut. 1978 Nov;19(11):1043-8
pubmed: 730071
Acta Physiol Scand. 1984 Feb;120(2):311-6
pubmed: 6324547
Naunyn Schmiedebergs Arch Pharmacol. 1986 Sep;334(1):110-5
pubmed: 3024021
Lancet. 1971 May 8;1(7706):939-41
pubmed: 4102271
Front Microbiol. 2018 Sep 20;9:2248
pubmed: 30294318
Lancet. 1969 Aug 9;2(7615):302-3
pubmed: 4184217
Gastroenterology. 1980 Apr;78(4):722-7
pubmed: 7353759
J Membr Biol. 1975 Nov 7;24(2):107-29
pubmed: 172636
Acta Physiol Scand. 1988 Jul;133(3):289-95
pubmed: 3227923
Scand J Gastroenterol. 1981 Apr;16(3):377-84
pubmed: 16435479
Paediatr Drugs. 2003;5(3):151-65
pubmed: 12608880
Scand J Gastroenterol. 1982 Aug;17(5):695-703
pubmed: 7178832
Gut. 1983 Jul;24(7):665-71
pubmed: 6345284
J Infect Dis. 1972 May;125(5):528-32
pubmed: 5023645
J Clin Invest. 1974 Sep;54(3):536-44
pubmed: 4369434
F1000Res. 2019 Sep 12;8:
pubmed: 31559013
Foods. 2014 Jun 30;3(3):394-402
pubmed: 28234326
Physiol Rev. 2018 Apr 1;98(2):919-1053
pubmed: 29537337
Trans R Soc Trop Med Hyg. 1979;73(1):3-9
pubmed: 442179
J Clin Invest. 1968 Dec;47(12):2600-7
pubmed: 5725277
Br J Pharmacol. 2005 Apr;144(7):994-1001
pubmed: 15711593
Lancet. 1982 Jun 12;1(8285):1317-9
pubmed: 6123635
N Engl J Med. 1983 Dec 15;309(24):1482-5
pubmed: 6316136
J Physiol. 1995 Mar 15;483 ( Pt 3):727-34
pubmed: 7539845
Lancet. 1973 Jul 7;2(7819):14-6
pubmed: 4123289
Gut. 1981 Nov;22(11):958-63
pubmed: 7308850
Gut. 1970 Sep;11(9):768-72
pubmed: 5473608
Acta Physiol Scand. 1987 Jan;129(1):115-25
pubmed: 3031931
N Engl J Med. 1971 May 20;284(20):1137-44
pubmed: 4324229
J Clin Invest. 1981 Jun;67(6):1687-94
pubmed: 6787081